Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia |
Apr 2024 |
Haematologica |
Aplastic Anemia |
Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities |
Apr 2024 |
Current Hematologic Malignancy Reports |
Myelodysplastic Syndromes (MDS) |
Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT |
Apr 2024 |
Blood |
Aplastic Anemia |
Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes |
Apr 2024 |
Journal of Internal Medicine |
Myelodysplastic Syndromes (MDS) |
Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes |
Apr 2024 |
Clinical Lymphoma, Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
Modified Delphi Panel Consensus Recommendations for Management of Severe Aplastic Anemia |
Apr 2024 |
Blood Advances |
Aplastic Anemia |
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes |
Apr 2024 |
Blood |
Myelodysplastic Syndromes (MDS) |
Advances in the management of higher-risk myelodysplastic syndromes: future prospects |
May 2024 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes |
May 2024 |
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
Exploring treatment strategies for paroxysmal nocturnal hemoglobinuria: an overview of registered clinical trials |
May 2024 |
Current Medical Research and Opinion |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |